FreshBurst Listerine protocol
This article was originally published in The Tan Sheet
Executive Summary
FDA approves Pfizer's proposed six-month, multi-center, 340-person gingivitis study in recent letter, noting if the trial determines "Listerine with fluoride is as effective as Listerine in reducing gingivitis and plaque," agency likely will grant the sodium fluoride/essential oils combination monograph status. FDA says it "will explore regulatory mechanisms for interim marketing under the OTC drug monograph procedures at [that] time." Pfizer modified its study proposal in October after an FDA feedback meeting (1"The Tan Sheet" Nov. 18, 2002, In Brief)...
You may also be interested in...
FreshBurst Listerine protocol
Pfizer proposes six-month, multi-center gingivitis study of 340 subjects at three clinical sites in Canada, Florida and Ohio for FreshBurst Listerine with Fluoride in Oct. 14 letter to FDA. Each center will have a principal investigator, who also may function as the site's clinical examiner. Pfizer originally had suggested a single-center study, which FDA opposed at an Aug. 27 feedback meeting (1"The Tan Sheet" Sept. 2, 2002, p. 14). Pfizer also agrees with FDA's suggestion to reduce the number of exclusion criteria. Pregnant women, diabetics, individuals with partial dentures or oral piercings are included under modified protocol, while those with "history of significant adverse events following use of oral hygiene products," "history of serious medical conditions" or alcoholism are excluded...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.